<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672958</url>
  </required_header>
  <id_info>
    <org_study_id>LuAA21004_303</org_study_id>
    <secondary_id>U1111-1114-2328</secondary_id>
    <nct_id>NCT00672958</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study Comparing the Efficacy and Safety of Lu AA21004 Versus Placebo in Acute Treatment of Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of once daily vortioxetine
      (Lu AA21004) in adults with major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested
      to treat depression in adults who have major depressive disorder (MDD). This study looked at
      MDD relief in people who took vortioxetine.

      The study enrolled 600 patients. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the two treatment groups—which remained undisclosed to the patient
      and study doctor during the study (unless there was an urgent medical need):

        -  Vortioxetine 5 mg

        -  Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but
           had no active ingredient.

      All participants were asked to take one capsule at the same time each day throughout the
      study.

      This multi-center trial was conducted in the United States. The overall time to participate
      in this study was approximately 94 days. Participants made 8 visits to the clinic, and were
      contacted by telephone 1 week, 2 weeks, and 4 weeks after the last dose of study drug for a
      follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4 and 5</time_frame>
    <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders in HAM-D24 Total Score by Study Visit</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
    <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in MADRS Remission at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Sustained Response in HAM-D24</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
    <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hamilton Anxiety Scale (HAM-A)</measure>
    <time_frame>Baseline and Weeks 1, 2, 4 and 6.</time_frame>
    <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression Scale-Severity of Illness</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Global Improvement Scale</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
    <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</measure>
    <time_frame>Baseline and Weeks 1, 4 and 6.</time_frame>
    <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Encapsulated immediate-release tablets.</description>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Lu AA21004</other_name>
    <other_name>Brintellix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vortioxetine placebo-matching capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffers from a major depressive episode (MDE) as the primary diagnosis according to
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
             (DSM-IV-TR) criteria.

          -  The reported duration of the current MDE is at least 3 months.

          -  Has a Montgomery Åsberg Depression Rating Scale total score greater than or equal to
             30.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant nor lactating from Screening throughout the
             duration of the study.

        Exclusion Criteria:

          -  Has received any investigational compound less than 30 days before Screening or 5
             half-lives prior to Screening, whichever is longer.

          -  Has received Lu AA21004 in a previous clinical study.

          -  Has 1 or more the following:

               -  Any current psychiatric disorder other than major depressive disorder as defined
                  in the DSM-IV-TR (as assessed by the Mini International Neuropsychiatric
                  Interview)

               -  Current or past history of: manic or hypomanic episode, schizophrenia, or any
                  other psychotic disorder, including major depression with psychotic features,
                  mental retardation, organic mental disorders, or mental disorders due to a
                  general medical condition as defined in the DSM-IV-TR.

               -  Any substance disorder (except nicotine and caffeine) within the previous 6
                  months as defined in the DSM-IV-TR.

               -  Presence or history of a clinically significant neurological disorder (including
                  epilepsy).

               -  Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple
                  sclerosis, Huntington disease, etc).

               -  Any Axis II disorder that might compromise the study.

          -  Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

               -  Narcotic analgesics

               -  Nonsteroidal anti-inflammatory drugs

               -  Rifampin

               -  Macrolide antibiotics

               -  Hormones (only thyroid hormone replacement, contraceptives [oral, patch],
                  estrogen and progesterone replacement therapy are allowed in chronic use)

               -  Hypoglycemic agents (chronic use is allowed)

               -  Insulin (chronic use is allowed)

               -  Systemic steroids

               -  Quinidine

               -  Antineoplastics

               -  Antiobesity agents

          -  Has a significant risk of suicide according to the investigator's opinion or has a
             score greater than or equal to 5 on item 10 (suicidal thoughts) of the Montgomery
             Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.

          -  The current depressive symptoms are considered by the investigator to have been
             resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.

          -  Has received electroconvulsive therapy within 6 months prior to Screening.

          -  Is currently receiving formal cognitive or behavioral therapy, systematic
             psychotherapy, or plans to initiate such therapy during the study.

          -  Has a clinically significant unstable illness, for example, hepatic impairment or
             renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine,
             neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue
             disorders, or metabolic disturbance.

          -  Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level
             greater than 1.5 times the upper limits of normal.

          -  Has a serum creatinine greater than 1.5 times the upper limits of normal.

          -  Has a previous history of cancer that had been in remission for less than 5 years
             prior to the first dose of study medication. This criterion does not include basal
             cell or Stage I squamous cell carcinoma of the skin.

          -  Has clinically significant abnormal vital signs as determined by the investigator.

          -  Has an abnormal electrocardiogram determined by the central reader and confirmed as
             clinically significant by the investigator.

          -  Has 1 or more laboratory values outside the normal range, based on the blood or urine
             samples taken at the Screening Visit, that are considered by the investigator to be
             clinically significant.

          -  Has a thyroid stimulating hormone value outside the normal range at Screening Visit
             that is determined to be clinically significant by the investigator.

          -  Has a disease or takes medication that, in the opinion of the investigator, could
             interfere with the assessments of safety, tolerability, or efficacy.

          -  Has previously enrolled in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estate</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brown Deer</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hull</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico, D.F.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21. doi: 10.1017/S1461145712000727. Epub 2012 Sep 11.</citation>
    <PMID>22963932</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>April 19, 2013</results_first_submitted>
  <results_first_submitted_qc>October 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2013</results_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Major Depressive Episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 47 investigative sites in the United States from 07 April 2008 to 12 November 2008.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of major depressive disorder were enrolled equally in 1 of 2 treatment groups, once a day placebo or 5 mg vortioxetine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="298">All randomized patients who received at least 1 dose of double-blind study drug.</participants>
                <participants group_id="P2" count="299">All randomized patients who received at least 1 dose of double-blind study drug.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="286">All safety set patients who had at least 1 valid postbaseline primary efficacy assessment.</participants>
                <participants group_id="P2" count="292">All safety set patients who had at least 1 valid postbaseline primary efficacy assessment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="236"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviations</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="300"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.4" spread="12.70"/>
                    <measurement group_id="B2" value="42.5" spread="13.04"/>
                    <measurement group_id="B3" value="42.4" spread="12.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian (White, including Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/ Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="266"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.53" spread="23.326"/>
                    <measurement group_id="B2" value="86.63" spread="23.528"/>
                    <measurement group_id="B3" value="88.08" spread="23.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.36" spread="9.815"/>
                    <measurement group_id="B2" value="168.67" spread="9.815"/>
                    <measurement group_id="B3" value="169.51" spread="9.843"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.84" spread="7.675"/>
                    <measurement group_id="B2" value="30.48" spread="8.217"/>
                    <measurement group_id="B3" value="30.66" spread="7.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.58" spread="17.757"/>
                    <measurement group_id="B2" value="96.22" spread="18.961"/>
                    <measurement group_id="B3" value="96.90" spread="18.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once monthly or less often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-to-6 times/week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-item Hamilton Depression Scale total score</title>
          <description>The 24-item Hamilton Depression Scale (HAM-D24) is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="5.50"/>
                    <measurement group_id="B2" value="32.7" spread="5.42"/>
                    <measurement group_id="B3" value="32.5" spread="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Åsberg Depression Rating Scale (MADRS) total score</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="3.41"/>
                    <measurement group_id="B2" value="34.1" spread="3.39"/>
                    <measurement group_id="B3" value="34.1" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Anxiety Scale Total Score</title>
          <description>Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="6.19"/>
                    <measurement group_id="B2" value="19.3" spread="5.24"/>
                    <measurement group_id="B3" value="19.4" spread="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression - Severity scale score</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="0.66"/>
                    <measurement group_id="B2" value="4.8" spread="0.68"/>
                    <measurement group_id="B3" value="4.8" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6</title>
        <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>The full analysis set, which includes all randomized participants who received at least 1 dose of study drug and had at least 1 postbaseline value for assessment of primary efficacy. Last observation carried forward (LOCF) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6</title>
          <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score range is from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with treatment and center as fixed factors and the baseline value as a covariate.</description>
          <population>The full analysis set, which includes all randomized participants who received at least 1 dose of study drug and had at least 1 postbaseline value for assessment of primary efficacy. Last observation carried forward (LOCF) was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.87" spread="0.662"/>
                    <measurement group_id="O2" value="-14.61" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline in HAM-D24 total score at Week 6 was tested at significance level 0.05. To control for multiplicity, subsequent endpoints were to be tested in a sequential testing procedure at significance level 0.025; as soon as an endpoint in a sequence was non-significant at 0.025, the testing procedure was stopped for all subsequent endpoints in that sequence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>Pre-specified sequential statistical testing procedure indicates that when p-value for change from baseline in HAMD-24 at Week 6 &gt;0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA), with treatment and center as fixed factors and baseline HAM-D24 as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.48</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</title>
        <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4 and 5</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</title>
          <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.03" spread="0.394"/>
                    <measurement group_id="O2" value="-5.96" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.30" spread="0.505"/>
                    <measurement group_id="O2" value="-9.05" spread="0.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n= 286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.05" spread="0.545"/>
                    <measurement group_id="O2" value="-11.73" spread="0.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.33" spread="0.579"/>
                    <measurement group_id="O2" value="-12.66" spread="0.568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.11" spread="0.628"/>
                    <measurement group_id="O2" value="-13.98" spread="0.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of change from Baseline at Week 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.901</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline at Week 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.701</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline at Week 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.11</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline at Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.670</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from Baseline at Week 5</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.304</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders in HAM-D24 Total Score by Study Visit</title>
        <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders in HAM-D24 Total Score by Study Visit</title>
          <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in MADRS Remission at Week 6</title>
        <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in MADRS Remission at Week 6</title>
          <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
          <population>Full analysis set; LOCF was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Sustained Response in HAM-D24</title>
        <description>A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Full analysis set. Participants with missing values were classified as nonsustained responders/remitters.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Sustained Response in HAM-D24</title>
          <description>A sustained response is defined as a ≥20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 5 and at least 50% decrease from Baseline at Week 6.</description>
          <population>Full analysis set. Participants with missing values were classified as nonsustained responders/remitters.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
        <population>Full analysis set. LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. Least square means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set. LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.88" spread="0.418"/>
                    <measurement group_id="O2" value="-6.38" spread="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.57" spread="0.530"/>
                    <measurement group_id="O2" value="-9.82" spread="0.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.48" spread="0.583"/>
                    <measurement group_id="O2" value="-12.76" spread="0.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.72" spread="0.624"/>
                    <measurement group_id="O2" value="-13.70" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.40" spread="0.673"/>
                    <measurement group_id="O2" value="-15.12" spread="0.664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.48" spread="0.708"/>
                    <measurement group_id="O2" value="-15.80" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hamilton Anxiety Scale (HAM-A)</title>
        <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4 and 6.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hamilton Anxiety Scale (HAM-A)</title>
          <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least squares means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="0.288"/>
                    <measurement group_id="O2" value="-3.21" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.92" spread="0.343"/>
                    <measurement group_id="O2" value="-4.77" spread="0.338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.52" spread="0.393"/>
                    <measurement group_id="O2" value="-6.88" spread="0.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.60" spread="0.419"/>
                    <measurement group_id="O2" value="-7.84" spread="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression Scale-Severity of Illness</title>
        <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression Scale-Severity of Illness</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.045"/>
                    <measurement group_id="O2" value="-0.40" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.061"/>
                    <measurement group_id="O2" value="-0.82" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.069"/>
                    <measurement group_id="O2" value="-1.08" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" spread="0.073"/>
                    <measurement group_id="O2" value="-1.20" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.079"/>
                    <measurement group_id="O2" value="-1.36" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="0.085"/>
                    <measurement group_id="O2" value="-1.46" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale-Global Improvement Scale</title>
        <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 5 and 6.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale-Global Improvement Scale</title>
          <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=281, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="0.048"/>
                    <measurement group_id="O2" value="3.46" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=286, 291)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="0.062"/>
                    <measurement group_id="O2" value="3.08" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="0.066"/>
                    <measurement group_id="O2" value="2.84" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.070"/>
                    <measurement group_id="O2" value="2.75" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" spread="0.073"/>
                    <measurement group_id="O2" value="2.65" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=286, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="0.076"/>
                    <measurement group_id="O2" value="2.57" spread="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</title>
        <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 4 and 6.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</title>
          <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=279, 286)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.81" spread="0.214"/>
                    <measurement group_id="O2" value="-2.73" spread="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=284, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.18" spread="0.272"/>
                    <measurement group_id="O2" value="-4.05" spread="0.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=284, 292)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.56" spread="0.313"/>
                    <measurement group_id="O2" value="-4.97" spread="0.307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6</title>
        <description>The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set where Baseline SF-36 data were available; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-item Short-form Health Survey (SF-36) at Week 6</title>
          <description>The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set where Baseline SF-36 data were available; LOCF was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.47" spread="1.277"/>
                    <measurement group_id="O2" value="6.87" spread="1.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role - physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.73" spread="1.569"/>
                    <measurement group_id="O2" value="14.41" spread="1.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="1.460"/>
                    <measurement group_id="O2" value="10.39" spread="1.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.65" spread="0.985"/>
                    <measurement group_id="O2" value="7.37" spread="0.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" spread="1.455"/>
                    <measurement group_id="O2" value="17.34" spread="1.440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.34" spread="1.687"/>
                    <measurement group_id="O2" value="22.01" spread="1.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role - emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.43" spread="1.756"/>
                    <measurement group_id="O2" value="20.76" spread="1.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.98" spread="1.401"/>
                    <measurement group_id="O2" value="20.00" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6</title>
        <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set where data were available; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 6</title>
          <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set where data were available; LOCF was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" spread="0.548"/>
                    <measurement group_id="O2" value="-6.69" spread="0.557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</title>
        <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Care Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</title>
          <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors the participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
          <population>Full analysis set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Any resource use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Any hospitalization-related services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Hospitalization related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Any sick leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sick leave related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Any resource use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Any hospitalization-related service</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Hospitalization related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Any sick leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: Sick leave related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are defined as adverse events whose onset occurred or intensity increased after the first dose of double-blind study drug through 30 days after permanent discontinuation of double-blind study drug.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Vortioxetine</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Puncture site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Initial insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

